Literature DB >> 10640791

CD40L activation in circulating platelets in patients with acute coronary syndrome.

Y Lee1, W H Lee, S C Lee, K J Ahn, Y H Choi, S W Park, J D Seo, J E Park.   

Abstract

The CD40-CD40L interaction, which was initially shown to have important roles in the T cell-mediated activation of B cells during humoral immune responses, is now known to have roles in activation of endothelial cells, smooth muscle cells, and macrophages within atherosclerotic plaques. Recently, CD40L expression was found in activated platelets in the thrombus in vivo and CD40L was reported to be responsible for the platelet-mediated activation of endothelial cells in vitro. To investigate the activation status of platelets in coronary artery disease patients, we tested expression levels of CD40L, and platelet-endothelial cell adhesion molecule-1 (PECAM-1/CD31) in platelets isolated from peripheral blood, using flow cytometric analysis. Twenty-nine patients with acute coronary syndrome (10 acute myocardial infarction and 19 unstable angina patients) were compared with 14 normal subjects or 14 stable angina patients. In platelets isolated from normal subjects, the expression of CD40L was not detected in all subjects. In the patients with acute coronary syndrome, the average level of CD40L showed a significant increase (p = 0.0028), while stable angina patients did not have any increase when compared to normal subjects. Patients with more complex lesions or vessel occlusion tended to have a high platelet CD40L level compared to patients who do not. The expression levels of CD31 were increased in a small portion of the ACS patients. These data indicate that the rupture of plaque and subsequent formation of thrombus may lead to the activation of CD40L expression in circulating platelets of ACS patients. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10640791     DOI: 10.1159/000006940

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  11 in total

Review 1.  A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass.

Authors:  Yajun Ren; Kirti Patel; Terry Crane
Journal:  J Extra Corpor Technol       Date:  2010-06

2.  Soluble CD40 ligand as a predictor of coronary artery disease and long-term clinical outcomes in stable patients undergoing coronary angiography.

Authors:  Matthew T Rondina; Jason M Lappé; John F Carlquist; Joseph B Muhlestein; Matthew J Kolek; Benjamin D Horne; Robert R Pearson; Jeffrey L Anderson
Journal:  Cardiology       Date:  2007-08-27       Impact factor: 1.869

Review 3.  Platelet reactivity and the identification of acute coronary syndromes in the emergency department.

Authors:  Chad E Darling; Alan D Michelson; Gregory A Volturo; Karin Przyklenk
Journal:  J Thromb Thrombolysis       Date:  2008-07-04       Impact factor: 2.300

4.  Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets.

Authors:  C D Garlichs; S Eskafi; D Raaz; A Schmidt; J Ludwig; M Herrmann; L Klinghammer; W G Daniel; A Schmeisser
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

5.  Levels of soluble TREM-like transcript 1 in patients presenting to the emergency department with chest pain.

Authors:  Omar L Esponda; Robert Hunter; José R Rivera Del Río; A Valance Washington
Journal:  Clin Appl Thromb Hemost       Date:  2014-08-21       Impact factor: 2.389

6.  Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling.

Authors:  K S Srinivasa Prasad; Patrick Andre; Ming He; Ming Bao; Jeanne Manganello; David R Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

7.  Premature labor: a state of platelet activation?

Authors:  Offer Erez; Roberto Romero; Debra Hoppensteadt; Jawed Fareed; Tinnakorn Chaiworapongsa; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Francesca Gotsch; Nandor Gabor Than; Edi Vaisbuch; Chong Jai Kim; Jimmy Espinoza; Pooja Mittal; Neil Hamill; Chia-Ling Nhan-Chang; Moshe Mazor; Sonia Hassan
Journal:  J Perinat Med       Date:  2008       Impact factor: 1.901

8.  PECAM-1 gene polymorphisms and soluble PECAM-1 level in rheumatoid arthritis and systemic lupus erythematosus patients: any link with clinical atherosclerotic events?

Authors:  Omer Nuri Pamuk; Hilmi Tozkir; Mehmet Sevki Uyanik; Hakan Gurkan; Fatih Saritas; Julide Duymaz; Salim Donmez; Metin Yazar; Gulsum Emel Pamuk
Journal:  Clin Rheumatol       Date:  2014-09-10       Impact factor: 2.980

9.  Systemic and coronary levels of CRP, MPO, sCD40L and PlGF in patients with coronary artery disease.

Authors:  Siew Wai Fong; Ling Ling Few; Wei Cun See Too; Boon Yin Khoo; Nik Nor Izah Nik Ibrahim; Shaiful Azmi Yahaya; Zurkurnai Yusof; Rosli Mohd Ali; Abdul Rashid Abdul Rahman; Get Bee Yvonne-Tee
Journal:  BMC Res Notes       Date:  2015-11-14

10.  Soluble CD40 Ligand and Oxidative Response Are Reciprocally Stimulated during Shiga Toxin-Associated Hemolytic Uremic Syndrome.

Authors:  Maria J Abrey Recalde; Romina S Alvarez; Fabiana Alberto; Maria P Mejias; Maria V Ramos; Romina J Fernandez Brando; Andrea C Bruballa; Ramon A Exeni; Laura Alconcher; Cristina A Ibarra; María M Amaral; Marina S Palermo
Journal:  Toxins (Basel)       Date:  2017-10-25       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.